The differences are as follows:
From the outer packaging, there is an additional sentence "Generic Drug Consistency Evaluation", which proves that this green drug is a generic drug, not the original drug.
Secondly, in terms of validity period, the current validity period of green is 1 year, while the validity period of white is 3 years, which means that this green generic drug can only stay in pharmacies/pharmacies for up to half a year, because the Food and Drug Administration It is required that the product is recalled when it is close to the shelf life (shelf life is less than half a year).
So the return rate for this type of generic drug will be very, very high.
Finally, from the perspective of the drug form, the original white tablet can be easily broken into two pieces, but the current green tablet is too hard and difficult to break. It is not convenient to adjust the dosage.
Precautions
1. Gout attacks
In the early stages of taking febuxostat, the frequency of gout attacks often increases. This is because blood uric acid concentration decreases, leading to mobilization of urate deposited in tissues. To prevent gout attacks during the initial stages of treatment, it is recommended to take nonsteroidal anti-inflammatory drugs or colchicine at the same time.
If gout attacks occur during febuxostat treatment, there is no need to discontinue febuxostat treatment. Gout should be treated accordingly according to the patient's specific situation.
2. Cardiovascular events
In randomized controlled studies, patients treated with febuxostat experienced cardiovascular thrombotic events (including cardiovascular death) compared with those treated with allopurinol. , non-fatal myocardial infarction, non-fatal stroke) with a higher probability.
The rate of febuxostat was 0.74/100 patient-years (95CI: 0.36-1.37), and that of allopurinol was 0.60/100 patient-years (95CI: 0.16-1.53). A causal relationship between febuxostat and cardiovascular thrombotic events has not been established. Pay attention to monitor the symptoms and signs of myocardial infarction and stroke when taking the drug.
3. Effects on the liver
There have been post-marketing reports of fatal and non-fatal liver failure in patients taking febuxostat, although these reports have determined that they There is insufficient information on causal relationships.
In randomized controlled studies, it was observed that transaminases could increase to more than 3 times the upper limit of the normal range (ULN) (the incidence rates in the febuxostat and allopurinol treatment groups were AST: 2, respectively) , 2; ALT: 3, 2). There was no dose-response relationship for these aminotransferase elevations.
Patients should have a liver function test (serum alanine aminotransferase [ALT], aspartate transferase [AST], alkaline phosphatase, and total bilirubin) before first starting febuxostat , this result is taken as the baseline level.
Patients who report symptoms such as fatigue, loss of appetite, right upper quadrant discomfort, soy-colored urine, or jaundice that may indicate liver damage should undergo prompt liver function testing.
In clinical terms, if a patient is found to have abnormal liver function (ALT more than 3 times the upper limit of the reference range), the medication should be discontinued and investigated to determine the possible cause. Febuxostat should not be reinstituted in these patients who have abnormal liver function tests and no other reasonable explanation.
If the patient's serum ALT exceeds the reference range by more than 3 times, and the serum total bilirubin exceeds the reference range by more than 2 times, and other causes are excluded, the patient is in serious condition at this time. At risk for drug-induced liver injury, these patients should not be reinstituted with febuxostat.
For those patients with small increases in serum ALT or bilirubin and other reasonable explanations, febuxostat should be treated with caution.
4. Secondary hyperuricemia
There is no research on the use of this product in patients with secondary hyperuricemia (including organ transplant recipients), so it is not recommended Use this product in patients with massively elevated urate levels (e.g. malignant diseases, Lesch-Nyhan syndrome). A few cases have shown that xanthine concentration in urine can be deposited in the urinary tract after a significant increase.
For the above content, please refer to Baidu Encyclopedia - Febuxostat Tablets